Trial · NCT03809143
Community Studies of Long Acting Buprenorphine (CoLAB)
NCT03809143, Phase 3, Unknown, The University of New South Wales
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Community Studies of Long Acting Buprenorphine (CoLAB). Trials, record NCT03809143. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03809143
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Community Studies of Long Acting Buprenorphine (CoLAB)
- NCT number
- NCT03809143
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 100 participants, actual
- Lead sponsor
- The University of New South Wales
- Conditions
- Opioid Dependence
- Interventions
- RBP-6000
- First posted
- 2019-01-18
- Last updated
- 2020-03-05
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant retention | Retention in dosing schedule at 48 weeks | To examine treatment retention at 48 weeks following initiation of monthly depot RBP-6000 buprenorphine injections in patients with opioid dependence transferred from a stable dose of sublingual buprenorphine. |
| Secondary | BUP-XR treatment retention and engagement in ongoing clinical care | 48 weeks | To examine BUP-XR treatment retention and engagement in ongoing clinical care at 48 weeks ortion of participants retained in treatment at 48 weeks following initiation of monthly depot buprenorphine injections and engaged in ongoing clinical care. Treatment retention is defined as remaining on active depot buprenorphine medication AND completing a clinical assessment at 48 weeks. |
| Secondary | Changes in opioid withdrawal | 48 weeks | Change in opioid withdrawal assessed by clinical opioid withdrawal scale (COWS) and subjective opioid withdrawal scale (SOWS) |
| Secondary | Changes in client-reported opioid craving | 48 weeks | Change in client-reported opioid craving assessed by opioid craving scale |
| Secondary | Changes in client-reported drug use | 48 weeks | Change in client-reported use of opioids and other drugs, assessed by the Australian Treatment Outcomes Profile (ATOP) instrument |
| Secondary | BUP-XR dosing schedule adherence | 48 weeks | To evaluate client utilisation of buprenorphine medication during the study, including BUP-XR dose variation, adherence with dosing schedule, and dose supplementation |
| Secondary | BUP-XR safety and tolerability | 48 weeks | To evaluate treatment safety and tolerability by monitoring adverse events, and events of clinical interest such as drug-drug interactions and pain management in clients treated with BUP-XR |
| Secondary | Changes in client-report pain and enjoyment | 48 weeks | To describe client-reported changes to pain and enjoyment of life, assessed by the Pain, Enjoyment, General Activity (PEG) scale |
| Secondary | Demographic factors associated with treatment retention | 48 weeks | To evaluate demographic factors (gender, age, education) associated with treatment retention, assessed by demographic questionnaire |
| Secondary | Client treatment satisfaction score | 48 weeks | Client-reported treatment satisfaction assessed by the Treatment Questionnaire for Medication Satisfaction (TQSM) |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03809143
GET https://conductscience.org/api/trials/v1/NCT03809143/registered